Taysha Gene Therapies Analyst Price Targets

Wall Street analyst price targets and consensus rating for Taysha Gene Therapies (TSHA).

Price Target Range — 12 Quarters

Analyst Consensus — 15 Analysts

3S.Buy

12Buy

Consensus RatingBuy# Analysts15Avg. Consensus PT$11Upside to Avg. PT+202.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 17, 2026	Wolfe Research	Kalpit Patel	Initiate	Outperform	—
Jul 21, 2026	Goldman Sachs	Salveen Richter	PT Raise	Buy	$11→$13
Jul 2, 2026	Citizens	Silvan Turkcan	Maintained	Market Outperform	$11
Jun 30, 2026	Needham	Gil Blum	Maintained	Buy	$12
Jun 30, 2026	Baird	Jack Allen	PT Raise	Outperform	$12→$15
Jun 23, 2026	BMO Capital	Keith Tapper	PT Raise	Outperform	$10→$14
Jun 23, 2026	B of A Securities	Tazeen Ahmad	PT Raise	Buy	$9→$10
Jun 23, 2026	Citizens	Silvan Tuerkcan	PT Raise	Market Outperform	$8→$11
Jun 22, 2026	Needham	Gil Blum	Maintained	Buy	$12
Apr 6, 2026	Canaccord Genuity	Whitney Ijem	PT Raise	Buy	$14→$17
Mar 19, 2026	Needham	Gil Blum	PT Raise	Buy	$10→$12
Mar 19, 2026	Chardan Capital	Geulah Livshits	Maintained	Buy	$12
Mar 3, 2026	Needham	Gil Blum	Maintained	Buy	$10
Jan 6, 2026	Chardan Capital	Geulah Livshits	Maintained	Buy	$12
Jan 5, 2026	Wells Fargo	Yanan Zhu	PT Raise	Overweight	$8→$11
Nov 5, 2025	Citizens	Silvan Tuerkcan	PT Raise	Market Outperform	$6→$8
Nov 5, 2025	Chardan Capital	Geulah Livshits	Maintained	Buy	$12
Oct 21, 2025	Raymond James	Christopher Raymond	Initiate	Strong Buy	$13
Oct 17, 2025	Chardan Capital	Geulah Livshits	Maintained	Buy	$12
Oct 17, 2025	Needham	Gil Blum	Maintained	Buy	$10

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Wolfe Research Initiates Coverage On Taysha Gene Therapies with Outperform Rating

Wolfe Research analyst Kalpit Patel initiates coverage on Taysha Gene Therapies (NASDAQ:TSHA) with a Outperform rating.

Benzinga Newsdesk

PRO
Goldman Sachs Maintains Buy on Taysha Gene Therapies, Raises Price Target to $13

Goldman Sachs analyst Salveen Richter maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Buy and raises the price target from $11 to $13.

Benzinga Newsdesk

PRO
Citizens Reiterates Market Outperform on Taysha Gene Therapies, Maintains $11 Price Target

Citizens analyst Silvan Turkcan reiterates Taysha Gene Therapies (NASDAQ:TSHA) with a Market Outperform and maintains $11 price target.

Benzinga Newsdesk

PRO
Baird Maintains Outperform on Taysha Gene Therapies, Raises Price Target to $15

Baird analyst Jack Allen maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Outperform and raises the price target from $12 to $15.

Benzinga Newsdesk

PRO
BMO Capital Maintains Outperform on Taysha Gene Therapies, Raises Price Target to $14

BMO Capital analyst Keith Tapper maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Outperform and raises the price target from $10 to $14.

Benzinga Newsdesk

PRO
B of A Securities Maintains Buy on Taysha Gene Therapies, Raises Price Target to $10

B of A Securities analyst Tazeen Ahmad maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Buy and raises the price target from $9 to $10.

Benzinga Newsdesk

Taysha Gene Therapies Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Taysha Gene Therapies Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Wolfe Research Initiates Coverage On Taysha Gene Therapies with Outperform Rating

PRO
Goldman Sachs Maintains Buy on Taysha Gene Therapies, Raises Price Target to $13

PRO
Citizens Reiterates Market Outperform on Taysha Gene Therapies, Maintains $11 Price Target

PRO
Baird Maintains Outperform on Taysha Gene Therapies, Raises Price Target to $15

PRO
BMO Capital Maintains Outperform on Taysha Gene Therapies, Raises Price Target to $14

PRO
B of A Securities Maintains Buy on Taysha Gene Therapies, Raises Price Target to $10

People Also Watch

People Also Watch

Taysha Gene Therapies Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Taysha Gene Therapies Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROWolfe Research Initiates Coverage On Taysha Gene Therapies with Outperform Rating

PROGoldman Sachs Maintains Buy on Taysha Gene Therapies, Raises Price Target to $13

PROCitizens Reiterates Market Outperform on Taysha Gene Therapies, Maintains $11 Price Target

PROBaird Maintains Outperform on Taysha Gene Therapies, Raises Price Target to $15

PROBMO Capital Maintains Outperform on Taysha Gene Therapies, Raises Price Target to $14

PROB of A Securities Maintains Buy on Taysha Gene Therapies, Raises Price Target to $10

People Also Watch

People Also Watch

PRO
Wolfe Research Initiates Coverage On Taysha Gene Therapies with Outperform Rating

PRO
Goldman Sachs Maintains Buy on Taysha Gene Therapies, Raises Price Target to $13

PRO
Citizens Reiterates Market Outperform on Taysha Gene Therapies, Maintains $11 Price Target

PRO
Baird Maintains Outperform on Taysha Gene Therapies, Raises Price Target to $15

PRO
BMO Capital Maintains Outperform on Taysha Gene Therapies, Raises Price Target to $14

PRO
B of A Securities Maintains Buy on Taysha Gene Therapies, Raises Price Target to $10